

## **Description of Additional Supplementary Files**

### **Supplementary Data 1. Sample metadata**

The first tab ('1M-scBloodNL\_metadata') provides phenotypical metadata of the 120 individuals included in this study. Tab 2 ('labels') provides an explanation for the column names in tab 1. The third tab ('DutchPopulation') shows the prevalence of a list of immune-mediated diseases in the Dutch population.

### **Supplementary Data 2. Cellranger metadata**

Output of the Cellranger pipeline per scRNA-seq library sample (pool of 8 individuals). Samples colored red were removed after quality control.

### **Supplementary Data 3. Quality control**

The sequential steps by which the cells are quality control filtered are shown and the number of cells lost during these steps are indicated.

### **Supplementary Data 4. Cell type markers**

Marker genes used for cell type annotation of clusters.

### **Supplementary Data 5. Differential Gene expression summary statistics**

Differential expression results in the low- and high-resolution cell types. Per tab one cell type is shown. The Bonferroni-corrected meta-analysis fold change and p-values of all genes that are significantly differentially expressed (Bonferroni-corrected version-chemistry meta-analysis p-value < 0.05) in at least one stimulation-timepoint combination of that cell type are listed.

### **Supplementary Data 6. Pathway analysis summary statistics**

Significant pathway analysis (BH-corrected p < 0.05) results per low- and high-resolution cell type using the corresponding upregulated genes as shown in Table S5.

### **Supplementary Data 7. eQTL mapping summary statistics eQTLgen lead-eSNP eQTL**

All cis-eQTL results (Z-score indicating strength and direction of the effect for given alternate allele) that were significant (FDR-corrected p < 0.05, indicated with an asterisk) in at least

one timepoint-stimulation combination across all major and subcell types (each tab represents one major cell type that is also analyzed separately by subtype, or a bulk-like sample combining all cells per individual). The nominal p-value of the bulk-like untreated (UT) condition is shown in each tab as a reference to compare cell-type-specific results against. The eQTL analysis was confined to those SNPs (MAF > 0.1) that were significant lead-eSNPs in bulk whole blood eQTLGen meta-analysis<sup>37</sup>.

#### **Supplementary Data 8. eQTL mapping summary statistics Genome-wide**

The cis-eQTL results (Z-score indicating strength and direction of the effect for given alternate allele) of all eQTL genes that were significant (FDR-corrected  $p < 0.05$ , indicated with an asterisk) in at least one timepoint-stimulation combination across all cell types (each tab represents one cell type, or a bulk-like sample combining all cells per individual). All SNPs (MAF > 0.1) were tested in this analysis, the lead-eSNP per timepoint-stimulation combination is provided.

#### **Supplementary Data 9. Response-QTL mapping analysis summary statistics**

The response-QTL results (Z-score indicating strength and direction of the effect for given alternate allele) that were significant (FDR-corrected  $p < 0.05$ , indicated with an asterisk) in at least one timepoint-stimulation combination across all cell types (each tab represents one cell type, or a bulk-like sample combining all cells per individual). The nominal p-value of the bulk-like untreated (UT) condition is shown in each tab as a reference to compare cell-type-specific results against. The response-QTL analysis was confined to those SNPs that were significant lead-eSNPs in at least one stimulation-timepoint combination and cell type in the eQTLGen<sup>37</sup>-confined analysis (from table S7).

#### **Supplementary Data 10. Genomic inflation analysis**

The amount of genomic inflation ( $\lambda$ ) of eQTL, non-response QTL and response-QTL SNPs based on six immune-mediated disease GWASes (separated per tab). The number of tested SNPs is reported for each category (eQTL, non-response QTL and response-QTL).

#### **Supplementary Data 11. Co-expression QTL analysis in monocytes summary statistics**

The co-expression QTL results in the monocytes from the 1M-scBloodNL dataset that are significant (10x Genomics version chemistry meta-analysis  $p <$  permutation-based significance threshold (2<sup>nd</sup> row of each tab)) in at least one stimulation-timepoint combination are shown. Spearman  $r$  correlations are shown for the significant co-expression QTLs, separated by 10x Genomics version chemistry.

**Supplementary Data 12. Co-expression QTL analysis SLE cohort in monocytes summary statistics**

The gene set that was significantly co-expressed with rs12230244-CLEC12A in the monocytes from the 1M-scBloodNL cohort (Table S11) was tested in an independent SLE and healthy control cohort. A permutation-based significance threshold (2<sup>nd</sup> row) was used to determine whether the meta-analysis p-value across all SLE or all healthy control sub-cohorts was significant. The spearman r correlation in each of the individual cohorts is indicated. The last column shows whether the co-expressed gene is part of the REACTOME interferon signaling pathway.